Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

ABSTRACT: PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

PROVIDER: PRJNA827164 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18774431_1.fastq.gz	Fastqsanger.gz
	SRR18774431_2.fastq.gz	Fastqsanger.gz
	SRR18774432_1.fastq.gz	Fastqsanger.gz
	SRR18774432_2.fastq.gz	Fastqsanger.gz
	SRR18774433_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

Project description:To investigate the potential mechanisms underlying PRMT3 regulation of GBM growth, we performed RNA-seq transcriptomic profiling of U251 GBM cells treated with lenti-ShCtrl and shPRMT3.

2022-11-08 | GSE200902 | GEO

HIF1a-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells

Project description:Upon antigen stimulation, the bioenergetic demands of T cells increase dramatically over the resting state. Although a role for the metabolic switch to glycolysis has been suggested to support increased anabolic activities and facilitate T cell growth and proliferation, whether cellular metabolism controls T cell lineage choices remains poorly understood. Here we report that the glycolytic pathway is actively regulated during the differentiation of inflammatory TH17 and Foxp3-expressing regulatory T cells (Treg), and controls cell fate determination. TH17 but not Treg-inducing conditions resulted in strong upregulation of the glycolytic activity and induction of glycolytic enzymes. Blocking glycolysis inhibited TH17 development while promoting Treg cell generation. Moreover, the transcription factor hypoxia-inducible factor 1a (HIF1a) was selectively expressed in TH17 cells and its induction required signaling through mTOR, a central regulator of cellular metabolism. HIF1a-dependent transcriptional program was important for mediating glycolytic activity, thereby contributing to the lineage choices between TH17 and Treg cells. Lack of HIF1a resulted in diminished TH17 development but enhanced Treg differentiation, and protected mice from autoimmune CNS inflammation. Our studies demonstrate that HIF1a-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. Naïve CD4 T cells from wild-type and HIF1a-deficient mice (in triplicates each group) were differentiated under TH17 conditions for 2.5 days, and RNA was analyzed by microarrays.

2011-06-07 | E-GEOD-29765 | biostudies-arrayexpress

HIF1a-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells

2011-06-07 | GSE29765 | GEO

Enhancing glioblastoma radiotherapy by COMT inhibition

Project description:Enhancing glioblastoma radiotherapy by COMT inhibition

| PRJNA993639 | ENA

HIF1alpha drives early induction of pluripotency through reprogramming of glycolytic metabolism

Project description:Gene expression analyis of two neonatal fibroblasts (BJ and HFF1), one adult dermal fibroblasts (NFH2), two BJ-derived human iPSCs (iB4 and iB5), two HFF1-derived iPSCs (iPS 2 and iPS4), four NFH2-derived iPSCs (OiPS3, OiPS6, OiPS8, OiPS16), one amniotic fluid cells and three derived iPSCs (lines 4, 5, 6, 10, and 41), two human ES cells (H1 and H9), neonatal fibroblasts transduced with the four retroviral factors (OKSM) after 24h, 48h, and 72h, neonatal fibroblasts treated with EDHB for 24h, 48h, and 72h, neonatal fibroblasts transduced with four factors and treated with EDHB for 24h, 48h, and 72h, neonatal fibroblasts knocked down for HIF1A (HIF1-KD) and for a scrambled sequence (SCR-KD) Total mRNA obtained from somatic cells (fibroblasts and amniotic fluid cells), pluripotent stem cells (iPSCs and hESCs), and somatic cells exposed to HIF1A activation or HIF1A suppsression in addition to the standard retroviral-based reprogramming.

2013-10-01 | E-GEOD-37709 | biostudies-arrayexpress

Changes in carbohydrate metabolism in alveolar epithelial type II cells in Ub-Cre and Hif1a loxp/loxp Ub cre mice in respnse to injurious mechanical ventilation (IMV)

Project description:IMV induces transcription of key glycolytic enzymes in alveolar epithelial type II mice IMV induced transcription of key glycolytic enzymes is HIF1A dependent

2023-03-02 | GSE220132 | GEO

SIRT3 opposes metabolic reprogramming of cancer cells through HIF1a destabilization

Project description:Tumor cells exhibit aberrant metabolism characterized by high glycolysis even in the presence of oxygen. This metabolic reprogramming, known as the Warburg effect, provides tumor cells with the substrates and redox potential required for the generation of biomass. Here, we show that the mitochondrial NAD-dependent deacetylase SIRT3 is a crucial regulator of the Warburg effect. SIRT3 loss promotes a metabolic profile consistent with high glycolysis required for anabolic processes in vivo and in vitro. Mechanistically, SIRT3 mediates metabolic reprogramming independently of mitochondrial oxidative metabolism and through HIF1a, a transcription factor that controls expression of key glycolytic enzymes. SIRT3 loss increases reactive oxygen species production, resulting in enhanced HIF1a stabilization. Strikingly, SIRT3 is deleted in 40% of human breast cancers, and its loss correlates with the upregulation of HIF1a target genes. Finally, we find that SIRT3 overexpression directly represses the Warburg effect in breast cancer cells. In sum, we identify SIRT3 as a regulator of HIF1a and a suppressor of the Warburg effect. RNA isolated from brown adipose tissue of SIRT3 WT and KO mice. 5 wild-type samples and 5 SIRT3 KO samples

2011-03-15 | E-GEOD-27309 | biostudies-arrayexpress

HIF1A signaling selectively supports proliferation of breast cancer in the brain [HIF1A KD]

Project description:Blood-borne metastasis to the brain is a major complication of breast cancer, but cellular pathways that enable cancer cells to selectively grow in the brain microenvironment are poorly understood. We find that cultured circulating tumor cells (CTCs), derived from blood samples of women with advanced breast cancer and directly inoculated into the mouse frontal lobe, exhibit striking differences in proliferative potential in the brain. Derivative cell lines generated by serial intracranial injections acquire selectively increased proliferative competency in the brain, with reduced orthotopic tumor growth. Increased Hypoxia Inducible Factor 1A (HIF1A)-associated signaling correlates with enhanced proliferation in the brain, and shRNA-mediated suppression of HIF1A or drug inhibition of HIF-associated glycolytic pathways selectively impairs brain tumor growth while minimally impacting mammary tumor growth. In clinical specimens, brain metastases have elevated HIF1A protein expression, compared with matched primary breast tumors, and, in patients with brain metastases, hypoxic signaling in CTCs predicts decreased overall survival. The selective activation of hypoxic signaling by metastatic cancers in the brain may be an opportunity for therapeutic intervention.

2020-10-17 | GSE156942 | GEO

TNFα/TNFR2 axis mediates natural killer cell proliferation by enhancing their glycolytic plasticity

Project description:TNFα/TNFR2 axis mediates natural killer cell proliferation by enhancing their glycolytic plasticity

| PRJNA986437 | ENA

SIRT3 opposes metabolic reprogramming of cancer cells through HIF1a destabilization

2011-03-15 | GSE27309 | GEO